(R)-4,5,6,7-Tetrahydro-N6-Propyl-2,6-Benzothiazolediamine

In quality-by-design (QbD) frameworks governing pramipexole dihydrochloride monohydrate manufacture under ICH Q7 and regional pharmacopoeial compendia, the (R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazolediamine entity is deployed as the primary chiral impurity reference marker. A validated reversed-phase chiral HPLC method—typically utilizing a protein-based Chiral-AGP column (100 × 4.0 mm, 5 μm) thermostatted at 25°C with a mobile phase of 50 mM sodium phosphate buffer pH 6.5 and acetonitrile in a 90:10 (v/v) ratio at 0.8 mL/min—resolves the (R)-enantiomer from the active (S)-isomer with a resolution factor R_s > 2.0. Detection is set at 264 nm, where the parent benzothiazole chromophore exhibits a molar extinction coefficient sufficient for a limit of quantification (LOQ) at 0.03% relative to the 1.0 mg/mL test concentration. Working standards are prepared by serial dilution of a primary standard whose chiral purity has been assigned through a combination of quantitative ¹H-NMR using 2,4-dinitrobenzoic acid as an internal calibrant and independent analysis by supercritical fluid chromatography coupled to a chiral Chiralpak AD-3S (150 × 4.6 mm, 3 μm) column. In accordance with ICH Q3A(R2) and pharmacopoeial harmonization, the reporting threshold is fixed at 0.05%, the identification threshold at 0.10%, and the qualification threshold at 0.15%; a typical acceptance criterion for (R)-isomer content in the final active pharmaceutical ingredient is not more than 0.15% area by HPLC, while in extended-release tablet formulations the limit is often tightened to 0.30% of the label claim per ICH Q3B(R2). Process development labs relying on kilo-scale batch records observe that impurity creep above 0.08% frequently traces back to incomplete racemization arrest during the final reductive amination step; this necessitates real-time monitoring with a 6-minute runtime UPLC-UV method on a sub-2-μm fully porous particle column to drive timely solvent swaps before the next unit operation.

What Pharmacological Insight Does the (R)-Enantiomer Provide at Human Dopamine D2_S and D3 Receptor Subtypes?

In radioligand displacement assays using [³H]7-OH-DPAT (specific activity 160 Ci/mmol) on membrane preparations from Chinese hamster ovary (CHO) cells stably expressing recombinant human D3 receptors, the (R)-enantiomer yields a specific binding isotherm with an affinity shift exceeding 250-fold relative to the therapeutically active (S)-enantiomer—published inhibition constant (K_i) values typically fall in the range 280–480 nM versus 0.5–1.2 nM. This profound stereoselectivity gap renders the compound an indispensable negative control in functional assays measuring [³⁵S]GTPγS incorporation at D2_short and D3 receptors, where the (R)-isomer fails to stimulate nucleotide exchange at concentrations up to 100 μM. In translational neuropharmacology, the tool is employed to confirm that observed neurotrophic factor release in primary mesencephalic cultures arises from D3-preferring agonism rather than off-target interactions; co-incubation with spiperone (10 μM) blocks residual signal, while raclopride (3 μM) partitions the D2 component. Experimental protocols uniformly specify pre-incubation of the (R)-enantiomer at 37°C for 30 minutes in modified Krebs-HEPES buffer (pH 7.4, containing 1.2 mM MgSO₄ and 0.1% ascorbic acid) to prevent oxidation of the catechol-like pharmacophore. Batch-to-batch variability in academic settings has been traced to residual trifluoroacetic acid (TFA) from HPLC purification; therefore, the dihydrochloride salt form is lyophilized twice from 0.1N HCl to ensure a counterion stoichiometry of 1:2.05 ± 0.05 as determined by ion chromatography before any dose-response study. Published data generated under NIH Assay Guidance Manual protocols confirm that an enantiomeric excess below 99.5% in the (R) material introduces an apparent partial agonist artifact due to contamination with the picomolar-affinity (S)-stereoisomer, driving a mandatory identity test by chiral HPLC with an area percent purity specification of ≥ 99.8% prior to use in any concentration-response curve.

A two-step derivatization sequence from the racemic free base forms the entry point into unsymmetrical C₂-chiral diimine ligand libraries for palladium-catalyzed asymmetric allylic alkylation. The racemic 4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazolediamine is first resolved via diastereomeric salt formation using L-(+)-tartaric acid (1.05 equivalents) in refluxing 95% ethanol; the (R)-enantiomer selectively crystallizes as the tartrate salt with an enantiomeric excess exceeding 99.0% after three recrystallization cycles monitored by a polarimetric detector (589 nm, specific rotation –58.3°). Liberation of the free base with 5% aqueous NaOH and extraction into tert-butyl methyl ether yields material of sufficient purity for subsequent condensation. The primary amine at the 2-position of the benzothiazole core is then selectively condensed with 4-substituted benzaldehydes (1.0 equivalent, e.g., 4-nitrobenzaldehyde) in anhydrous toluene containing activated 4Å molecular sieves under a nitrogen atmosphere at 70°C for 6 hours to furnish the mono-imine intermediate. Subsequent reaction of the secondary N6-propylamine with a second, electronically differentiated aldehyde (2,4-dimethoxybenzaldehyde, 1.2 equivalents) at 50°C in the presence of triethylamine (2.0 equivalents) completes the unsymmetrical N,N'-diimine framework. Complexation with [Pd(C₃H₅)Cl]₂ (2.5 mol% Pd) in dichloromethane at room temperature forms the active pre-catalyst. When evaluated in a standard test reaction—alkylation of rac-1,3-diphenyl-2-propenyl acetate with dimethyl malonate using N,O-bis(trimethylsilyl)acetamide (BSA, 3.0 equivalents) and a catalytic amount of potassium acetate (2 mol%) at –20°C—the (R)-diamine-derived catalyst affords the (S)-product in 87% enantiomeric excess with a turnover frequency exceeding 120 h^–1 at complete conversion. The rigid tetrahydrobenzothiazole spacer prevents competing β-hydride elimination pathways that plague flexible aliphatic diamine backbones, a stability advantage confirmed by ³¹P NMR trapping with triphenylphosphine oxide.

Confirming In Vitro Oxidative N-Dealkylation Metabolites Demands an (R)-Isomer Spiking Protocol

During microsomal incubation experiments designed to map the metabolic soft spots of the (S)-configured drug substance, the (R)-enantiomer is introduced as a chromatographic retention time marker and as a standard for quantifying N-dealkylation products. Pooled human liver microsomes (HLM, 0.5 mg/mL protein) are incubated with NADPH-regeneration system (1.0 mM NADP⁺, 5.0 mM glucose-6-phosphate, 1.0 U/mL glucose-6-phosphate dehydrogenase) in 100 mM potassium phosphate buffer (pH 7.4) containing 3.0 mM MgCl₂. The (R)-substrate is added at 1.0 μM from a concentrated 10 mM DMSO stock, and incubations are quenched at time points 0, 5, 15, 30, and 60 minutes with an equal volume of ice-cold acetonitrile containing 0.1% formic acid and internal standard (tolbutamide-D9, 50 ng/mL). Samples are clarified by centrifugation at 20,000 g for 10 minutes at 4°C and analyzed by UHPLC-Q-TOF mass spectrometry using a HSS T3 C18 column (100 × 2.1 mm, 1.8 μm) with gradient elution from 5% to 95% acetonitrile in 0.1% aqueous formic acid over 8 minutes. The major phase I metabolite—resulting from oxidative N-dealkylation of the propylamine side chain to furnish the free primary amine at the 6-position—elutes at 3.45 minutes with [M+H]⁺ m/z 184.0902 (calculated 184.0901, mass error 0.5 ppm). By spiking synthetic (R)-metabolite standard at five calibration levels 0.05–2.00 μM into blank matrix, analysts construct a weighted (1/x²) linear regression with correlation coefficient r² > 0.995. This protocol enables differentiation of the dealkylation pathway from ring hydroxylation, which produces an isobaric hydroxylated species that chromatographically separates under the 0.1% heptafluorobutyric acid ion-pairing modification. The dihydrochloride salt of the (R)-metabolite, prepared by treatment with HCl gas in diethyl ether followed by recrystallization from ethanol/acetone (1:4), is stored desiccated at –20°C under argon to prevent amine oxidation; a certificate of analysis stating isotopic purity > 99% and residual solvent levels compliant with ICH Q3C Option 2 is generated for every batch used in regulatory submission studies.

When Simulated Moving Bed Chromatography Switches from Batch to Steady-State for Multi-Kilogram Enantioseparation

The resolution of racemic 4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazolediamine at production scale frequently transitions to continuous simulated moving bed (SMB) chromatography once annual demand surpasses 500 kg of single enantiomer. A 6-zone, 8-column SMB unit (column diameter 15 cm, bed length 10 cm) packed with a Chiralpak IA 20 μm immobilized amylose tris(3,5-dimethylphenylcarbamate) stationary phase is operated with a mobile phase composed of methanol/diethylamine 100:0.1 (v/v) at 30°C. The racemate feed is dissolved in the mobile phase at a concentration of 65 g/L and injected via a binary pump maintaining a feed flow rate of 28 mL/min. Under optimized internal flow rates—zone I 180 mL/min, zone II 135 mL/min, zone III 155 mL/min, and switching time 3.8 minutes—the (S)-enantiomer elutes in the extract stream with an optical purity of 99.7% ee while the (R)-enantiomer accumulates in the raffinate stream at 99.2% ee. The raffinate fraction is concentrated under reduced pressure at 40°C using a thin-film evaporator before crystallization as the L-tartrate salt from 2-propanol/water (95:5 v/v), which increases the enantiomeric excess to 99.9% with a total process yield of 84% across the crystallization step. The entire operation reaches steady state within 11 cycle switches and maintains stable performance for more than 2,000 hours before the chiral stationary phase requires regeneration with pure methanol at 50°C. Back-pressure monitoring at the column outlet (typically 18–22 bar) serves as an early indicator of frit blockage due to poorly filtered feed; inline 2 μm stainless steel frits and a prophylactic guard column containing the same CSP extend the main column lifetime, while rigorous water content control in the mobile phase below 0.05% prevents hydrolysis of the amylose carbamate linkages. The capability to process 8.2 kg racemate per day on a single SMB skid aligns with just-in-time delivery schedules demanded by contract manufacturing organizations operating under cGMP (21 CFR Part 211).

Derivatization with (R)-(-)-α-methoxy-α-trifluoromethylphenylacetyl chloride (Mosher’s acid chloride, 1.2 equivalents) in dry dichloromethane containing triethylamine (2.5 equivalents) at 0°C produces the corresponding di-Mosher amide diastereomers in quantitative yield. The reaction mixture is stirred for 3 hours and then quenched with 5% NaHCO₃, washed, dried over Na₂SO₄, and analyzed without further purification by 470 MHz ¹⁹F NMR in CDCl₃. The trifluoromethyl resonances of the (R,R)- and (R,S)-diastereomers consistently resolve at –68.53 ppm and –68.89 ppm downfield from CCl₃F, with integration precision better than ±0.5% when a relaxation delay of 10 seconds and a pulse angle of 30° are employed. This method establishes the (R)-enantiomer as an independent internal control for calibrating enantioenrichment during asymmetric synthesis scale-up campaigns; process chemists intermittently withdraw 0.5 mL aliquots from a kinetic resolution reaction, remove the aprotic solvent under a nitrogen stream, and derivatize the concentrated residue. The entire derivatization-analysis cycle is completed within 25 minutes, compatible with real-time process decision-making. The (R)-diamine Mosher amide also serves as a reference for setting integration thresholds in qNMR sequences used to assign purity to in-house primary standards, and it is routinely included as a system suitability solution to verify spectral resolution after a magnet shim.

For positron emission tomography (PET) imaging studies targeting dopamine D3 receptor density in the ventral striatum and substantia nigra, the secondary propylamine side chain of the (R)-enantiomer provides a direct precursor for N-[¹⁸F]fluoropropyl radiolabeling. The free base is reacted with 2-[¹⁸F]fluoroethyl tosylate (prepared by nucleophilic substitution of 2-tosyloxyethyl triflate with [¹⁸F]fluoride/Kryptofix 2.2.2/K₂CO₃ complex in acetonitrile at 85°C for 10 minutes) in anhydrous DMSO at 120°C for 20 minutes. The crude radiolabeled product is purified by semi-preparative HPLC on a Luna C18(2) column (250 × 10 mm, 5 μm) using 0.1% TFA in water:acetonitrile (70:30) at 4 mL/min. The fraction eluting at 12.2–13.0 minutes is collected, diluted with water, trapped on an activated Oasis HLB cartridge, eluted with 0.5 mL ethanol, and formulated in phosphate-buffered saline (pH 7.2, 10% ethanol). This fully automated procedure, executed on a commercial GE TRACERlab FX_FN module, delivers 18–25 GBq of injectable radiopharmaceutical within 45 minutes from end-of-bombardment with a radiochemical purity exceeding 99.0% and a molar activity of 80–120 GBq/μmol at end-of-synthesis. The resulting tracer is formulated into a sterile multi-dose vial with a concentration of < 3.5 μg/mL total mass dose to avoid receptor occupancy artifacts. The (R)-configured byproduct from the radiolabeling of the clinically used (S)-¹⁸F-tracer serves concurrently as the unlabeled manufacturer’s working standard for radio-HPLC identity confirmation (retention time window ± 2% of the reference) and for cold-run validation before each GMP production campaign. Quality release testing follows Eur. Ph. monograph 1325 specifications for PET radiopharmaceuticals, including tests for bacterial endotoxins (LAL test, < 1.75 EU/mL), sterility, and residual Kryptofix content (GC limit 0.5 mg/mL).

Brush-Type Chiral Stationary Phase Manufacture: N-Acylation with 3-(Triethoxysilyl)propyl Isocyanate

Immobilization of the (R)-enantiomer onto microparticulate silica gel yields Pirkle-type chiral stationary phases (CSPs) for enantioresolution of neutral and weakly acidic aromatic analytes. Kromasil spherical silica (5 μm, 100 Å) is first dried at 150°C for 4 hours under vacuum to remove physisorbed water, achieving a surface silanol density of 7.8 ± 0.5 μmol/m² by Karl Fischer titration. A suspension of the silica in anhydrous toluene containing 3-(triethoxysilyl)propyl isocyanate (2.5 equivalents per m² surface area) and a catalytic amount of dibutyltin dilaurate is refluxed under nitrogen for 24 hours, yielding isocyanate-functionalized silica with a carbon loading of 8.2–8.5% by elemental analysis. The (R)-diamine, dissolved in a mixture of dichloromethane/pyridine (9:1 v/v), is then coupled at 0°C over 12 hours; the nucleophilic attack of the less-hindered primary aromatic amine on the supported isocyanate group proceeds selectively, leaving the propyl-substituted secondary amine free as a secondary recognition site. Residual isocyanate groups are end-capped with n-propylamine (1.0 mL per 10 g silica). The resulting CSP is slurry-packed into a 250 × 4.6 mm stainless steel column under 8,000 psi using methanol as the packing solvent. Evaluation with a test mixture of 1,1’-bi-2-naphthol enantiomers under normal-phase conditions (n-hexane/2-propanol/TFA 85:15:0.1, 1.0 mL/min, UV 254 nm) demonstrates separation factors α = 1.32–1.48 and resolution R_s > 2.8, metrics that remain stable for more than 1,500 injections when the column is stored in isopropanol. The presence of both a hydrogen-bond donor (the free propylamine hydrogen) and an acceptor (the thiazole nitrogen) on the rigid chiral selector scaffold creates a constrained chiral pocket that discriminates substrates through a combination of π-π stacking with the benzothiazole ring and directional hydrogen bonding with the analyte’s hydroxy or carbonyl groups. Tablet excipient compatibility studies using the (R)-CSP also confirm the absence of leachables when in contact with mobile phases containing up to 0.5% trifluoroacetic acid or 20 mM ammonium acetate buffer (pH 6.0), supporting its use in analytical quality control workflows compliant with USP General Chapter <621>.